David Novak
Stock Analyst at Raymond James
(1.14)
# 3,579
Out of 4,865 analysts
9
Total ratings
44.44%
Success rate
-9.31%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Novak
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZYME Zymeworks | Downgrades: Outperform | $74 | $12.24 | +504.58% | 6 | Dec 10, 2021 | |
| LPTX Leap Therapeutics | Maintains: Outperform | $25 → $35 | $0.38 | +9,019.33% | 2 | Mar 2, 2021 | |
| CBIO GlycoMimetics | Maintains: Outperform | $300 → $270 | $13.27 | +1,934.66% | 1 | Feb 4, 2021 |
Zymeworks
Dec 10, 2021
Downgrades: Outperform
Price Target: $74
Current: $12.24
Upside: +504.58%
Leap Therapeutics
Mar 2, 2021
Maintains: Outperform
Price Target: $25 → $35
Current: $0.38
Upside: +9,019.33%
GlycoMimetics
Feb 4, 2021
Maintains: Outperform
Price Target: $300 → $270
Current: $13.27
Upside: +1,934.66%